Overview Financials News + Filings Key Docs Charts Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NeuroDerm Ltd. (NDRM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"NeuroDerm Announces Second Quarter 2017 Financial Results REHOVOT, Israel – August 3, 2017 – NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced financial results for the second quarter ended June 30, 2017. Recent Highlights · On July 24, 2017, NeuroDerm entered into a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 billion in cash. A special meeting of shareholders to approve the transaction is expected to be held on September 12, 2017. Assuming typical regulatory and shareholder approval timeframes, NeuroDerm currently anticipates the transaction will close in the fourth quarter of 2017. · On June 6, 2017, NeuroDerm announced that the main de..." |
|
| 05/12/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 04/03/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
|
|